-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target

Benzinga·04/08/2025 11:24:22
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price target.